We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effect of Gabapentin on Pain of the Second Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02127853
Recruitment Status : Unknown
Verified April 2014 by Hee-Pyoung Park, Seoul National University Hospital.
Recruitment status was:  Recruiting
First Posted : May 1, 2014
Last Update Posted : May 12, 2015
Information provided by (Responsible Party):
Hee-Pyoung Park, Seoul National University Hospital

Brief Summary:
Gabapentin pretreatment may reduce hyperalgesia occurring at the second surgery in serial, bilateral cataract surgery.

Condition or disease Intervention/treatment Phase
Hyperalgesia Drug: gabapentin Drug: placebo Phase 4

Detailed Description:
Hyperalgesia occurring at the second operation in bilateral eye surgery is well known, and mechanism of central sensitization might be involved. Gabapentin is known to lower the effect of central sensitization, and its effect on acute postoperative pain has been reported. Therefore, pretreatment of gabapentin after first operation may reduce the pain at second operation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery
Study Start Date : July 2014
Estimated Primary Completion Date : February 2016
Estimated Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: Gabapentin
gabapentin pretreatment
Drug: gabapentin
100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery

Placebo Comparator: Placebo
placebo drug pretreatment
Drug: placebo
the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery

Primary Outcome Measures :
  1. proportion of subjects who answer that "pain was greater" in the second eye surgery [ Time Frame: Intra operative (pain while fluid injection to anterior chamber) ]

Secondary Outcome Measures :
  1. perioperative pain [ Time Frame: end of surgery, post-op 1hr at PACU, at out-patient ward, post-op 1 day ]
    evaluation of overall perioperative pain

Other Outcome Measures:
  1. satisfaction [ Time Frame: intra operative ]
    evaluation of satisfaction of both operator and patient

  2. anxiety [ Time Frame: baseline (at OR room arrival, just before sterile draping) ]
    evaluation of patient's anxiety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patient of ASA(American Cociety of Anesthesiology) class I, II, III between age 20 to 80, scheduled for serial bilateral cataract surgery(1 weel interval)

Exclusion Criteria:

  • refuse to participate
  • BMI<16 or BMI >30
  • severe cardiovascular, pulmonary, renal disease
  • alcohol or drug abuse
  • currently taking CNS(central nervous system) inhibitory drugs
  • taking antiacids
  • depressive disorder pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02127853

Layout table for location contacts
Contact: Heepyoung Park, MD,PhD 82-2-2072-2466 hppark@snu.ac.kr
Contact: Eugene Kim, MD 82-2-2072-2469 tomomie@hanmail.net

Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-799
Contact: Heepyoung Park, MD, PhD    82-2-2072-2466    hppark@snu.ac.kr   
Contact: Eugene Kim, MD    82-2-2072-2469    tomomie@hanmail.net   
Sponsors and Collaborators
Seoul National University Hospital
Layout table for additonal information
Responsible Party: Hee-Pyoung Park, associate professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT02127853    
Other Study ID Numbers: SerialCataractGaba
First Posted: May 1, 2014    Key Record Dates
Last Update Posted: May 12, 2015
Last Verified: April 2014
Keywords provided by Hee-Pyoung Park, Seoul National University Hospital:
serial cataract surgery
central sensitization
Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Eye Diseases
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antimanic Agents